Evaluation of the immunogenicity of a CaCl2 extract from Neisseria meningitidis group Y
- 1 September 1982
- journal article
- research article
- Published by Canadian Science Publishing in Canadian Journal of Microbiology
- Vol. 28 (9) , 1022-1031
- https://doi.org/10.1139/m82-153
Abstract
Cross-protection has already been demonstrated in mice after vaccination with a CaCl2 extract from the Neisseria meningitides group Y Slaterus strain. The immunogenicity of such extracts from group Y cells, cultivated in a fermenter in Neisseria chemically defined medium, against virulent groups A, B, and C meningococci has been evaluated by two different animal models and a microbactericidal procedure. The mouse challenge system has revealed that the active cross-production observed 7 days after a single immunization with the extract was probably nonspecific, since bacillus Calmette-Guérin gave similar results. However, after three vaccinations, active cross-protection was observed, mainly against the strains of groups B and C, for at least 35 days after the last injection. In the mouse bacteremia model, the extract had a protective effect mainly against the homologous group Y strain but in a few experiments a significant protection was also obtained against the strains of groups A and B. The microbactericidal test revealed that even after three injections of mice, guinea pigs, or humans with the extract only the homologous bactericidal activity was induced. Since there was no close correlation between the results obtained with the two animal models and also with the microbactericidal procedure, no definitive conclusion can be drawn on the protective potential of our extract.This publication has 9 references indexed in Scilit:
- Clinical and Serological Evaluation of a Meningococcal Polysaccharide Vaccine Groups A, C, Y, and W135Experimental Biology and Medicine, 1982
- Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia modelInfection and Immunity, 1979
- Complex of Meningococcal Group B Polysaccharide and Type 2 Outer Membrane Protein Immunogenic in ManJournal of Clinical Investigation, 1979
- Safety and Immunogenicity of a Neisseria meningitidis Type 2 Protein Vaccine in Animals and HumansThe Journal of Infectious Diseases, 1978
- Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.The Journal of Experimental Medicine, 1978
- Strain-specific variation in the protein and lipopolysaccharide composition of the group B meningococcal outer membraneJournal of Bacteriology, 1976
- Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitisThe Journal of Pediatrics, 1976
- STATISTICAL TABLES TO DETECT SIGNIFICANCE BETWEEN FREQUENCIES IN 2 SMALL SAMPLES, WITH PARTICULAR REFERENCE TO BIOLOGICAL ASSAYS1976
- A CHEMICALLY DEFINED PROTEIN-FREE LIQUID MEDIUM FOR CULTIVATION OF SOME SPECIES OF NEISSERIA1967